Merck signs exclusive global license for SciBrunch's preclinical KRAS G12D inhibitor SPR2015 for $400M upfront

Merck signed an exclusive global license agreement with SciBrunch Therapeutics for SPR2015, an investigational preclinical oral KRAS G12D inhibitor, for $400M upfront plus additional payments. Merck will record a pre-tax charge of $0.13 per share in Q3.

Detected & updated continuously · Source: Nebula